IL262708B - Di-substituted pyrazole compounds for the treatment of diseases - Google Patents
Di-substituted pyrazole compounds for the treatment of diseasesInfo
- Publication number
- IL262708B IL262708B IL262708A IL26270818A IL262708B IL 262708 B IL262708 B IL 262708B IL 262708 A IL262708 A IL 262708A IL 26270818 A IL26270818 A IL 26270818A IL 262708 B IL262708 B IL 262708B
- Authority
- IL
- Israel
- Prior art keywords
- pyrazole
- quite
- diseases
- treatment
- converted compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330049P | 2016-04-29 | 2016-04-29 | |
| PCT/US2017/030261 WO2017190086A1 (en) | 2016-04-29 | 2017-04-28 | Di-substituted pyrazole compounds for the treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL262708A IL262708A (en) | 2018-12-31 |
| IL262708B true IL262708B (en) | 2022-04-01 |
Family
ID=59215955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL262708A IL262708B (en) | 2016-04-29 | 2018-10-31 | Di-substituted pyrazole compounds for the treatment of diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11497738B2 (https=) |
| EP (1) | EP3448851B8 (https=) |
| JP (1) | JP6931695B2 (https=) |
| KR (1) | KR102498741B1 (https=) |
| CN (1) | CN109476635B (https=) |
| AU (1) | AU2017258781C1 (https=) |
| CA (1) | CA3022395C (https=) |
| ES (1) | ES2912921T3 (https=) |
| IL (1) | IL262708B (https=) |
| MX (1) | MX382630B (https=) |
| WO (1) | WO2017190086A1 (https=) |
| ZA (1) | ZA201807509B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2932187T3 (es) | 2016-09-07 | 2023-01-16 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| EP3746070A4 (en) * | 2018-01-29 | 2021-09-01 | Capulus Therapeutics, LLC | SREBP INHIBITORS WITH A 6-LINKED CENTER RING |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN114728909A (zh) * | 2019-09-25 | 2022-07-08 | 韩国原子力医学院 | 含有新型三氟甲基苯基吡唑衍生物作为活性成分用于预防或治疗癌症的组合物 |
| KR102663365B1 (ko) * | 2019-09-25 | 2024-05-08 | 한국원자력의학원 | 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| EP4096659A4 (en) * | 2020-01-27 | 2023-10-18 | Capulus Therapeutics, LLC | Srebp inhibitors comprising a thiophene central ring |
| KR102258451B1 (ko) * | 2020-11-17 | 2021-05-31 | 주식회사 하이센스바이오 | 지방간질환의 예방 또는 치료용 조성물 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3406329A1 (de) | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| CZ284157B6 (cs) | 1992-12-17 | 1998-08-12 | Pfizer Inc. | Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| JP3303044B2 (ja) | 1994-12-21 | 2002-07-15 | エヌイーシートーキン株式会社 | 永久磁石とその製造方法 |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6130217A (en) | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| WO1998035957A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6531478B2 (en) * | 2000-02-24 | 2003-03-11 | Cheryl P. Kordik | Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| ATE407132T1 (de) | 2000-12-05 | 2008-09-15 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| AU2003216581A1 (en) * | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
| ES2379076T3 (es) | 2002-12-02 | 2012-04-20 | Astellas Pharma Inc. | Derivados de pirazol útiles como inhibidores de COX-I |
| AU2004200420A1 (en) | 2003-03-11 | 2004-09-30 | Astellas Pharma Inc. | Inhibitor of cyclooxygenase |
| RU2005134670A (ru) | 2003-04-10 | 2006-06-10 | Аванир Фармасьютикалс (Us) | Производные имидазола для лечения аллергических и гиперпролиферативных нарушений |
| WO2005044194A2 (en) | 2003-10-28 | 2005-05-19 | Pharmacia Corporation | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| TW200526641A (en) | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| EP1789498A1 (en) | 2004-09-02 | 2007-05-30 | Clariant International Ltd. | Use of thiazolyl-pyridinium dyes for optical data recording |
| EP2402323A3 (en) | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| AU2006210503B2 (en) | 2005-02-03 | 2009-09-03 | Irm Llc | Compounds and compositions as PPAR modulators |
| CN101203220A (zh) | 2005-06-28 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 新用途 |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US20160221999A1 (en) | 2007-02-02 | 2016-08-04 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US9085566B2 (en) | 2007-02-02 | 2015-07-21 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and related disorders |
| US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
| US9233941B2 (en) | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
| JP5461197B2 (ja) | 2007-02-02 | 2014-04-02 | ベイラー カレッジ オブ メディスン | 代謝障害を処置するための組成物および方法 |
| DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| CN101918389A (zh) | 2007-11-02 | 2010-12-15 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| TWI453019B (zh) * | 2007-12-28 | 2014-09-21 | Abbvie Deutschland | 甲醯胺化合物 |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| WO2011038261A1 (en) | 2009-09-24 | 2011-03-31 | Selexagen Therapeutics, Inc. | Heterocyclic kinase inhibitors |
| JP5640091B2 (ja) | 2009-10-01 | 2014-12-10 | カディラ・ヘルスケア・リミテッド | 脂質異常症および関連疾患の治療のための化合物 |
| CN102933079B (zh) | 2010-03-04 | 2016-02-17 | 默沙东公司 | 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途 |
| WO2011133444A1 (en) | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| BR112014006940A2 (pt) * | 2011-09-23 | 2017-04-04 | Bayer Ip Gmbh | uso de derivados de ácido 1-fenilpirazol-3-carboxílico 4-substituído como agentes contra estresse abiótico em plantas |
| SI3038622T1 (en) | 2013-08-28 | 2018-08-31 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
| WO2015031710A1 (en) | 2013-08-29 | 2015-03-05 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and body weight related disorders |
| AU2014345594B2 (en) * | 2013-11-05 | 2018-11-08 | Elanco Animal Health Gmbh | Substituted benzamides for the treatment of arthropods |
| EP3096761A1 (en) | 2014-01-24 | 2016-11-30 | Confluence Life Sciences, Inc. | Substituted pyroolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases |
| WO2016073826A1 (en) | 2014-11-07 | 2016-05-12 | Fgh Biotech, Inc. | Synthesis of fatostatin based polycyclic compounds |
| AU2015369712B2 (en) | 2014-12-22 | 2020-05-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Mutant IDH1 inhibitors useful for treating cancer |
| US10328064B2 (en) | 2014-12-23 | 2019-06-25 | Fgh Biotech, Inc. | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| EP3265457A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Sterol regulatory element-binding proteins (srebps) inhibitors |
| US10183015B2 (en) | 2015-03-04 | 2019-01-22 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
| CN105294584A (zh) | 2015-11-30 | 2016-02-03 | 中国医科大学 | 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途 |
| ES2932187T3 (es) | 2016-09-07 | 2023-01-16 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades |
-
2017
- 2017-04-28 KR KR1020187033931A patent/KR102498741B1/ko active Active
- 2017-04-28 JP JP2019508167A patent/JP6931695B2/ja active Active
- 2017-04-28 US US16/097,211 patent/US11497738B2/en active Active
- 2017-04-28 WO PCT/US2017/030261 patent/WO2017190086A1/en not_active Ceased
- 2017-04-28 ES ES17733180T patent/ES2912921T3/es active Active
- 2017-04-28 MX MX2018013221A patent/MX382630B/es unknown
- 2017-04-28 CN CN201780034410.XA patent/CN109476635B/zh active Active
- 2017-04-28 CA CA3022395A patent/CA3022395C/en active Active
- 2017-04-28 EP EP17733180.8A patent/EP3448851B8/en active Active
- 2017-04-28 AU AU2017258781A patent/AU2017258781C1/en active Active
-
2018
- 2018-10-31 IL IL262708A patent/IL262708B/en unknown
- 2018-11-08 ZA ZA2018/07509A patent/ZA201807509B/en unknown
-
2022
- 2022-09-08 US US17/940,640 patent/US20230119547A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018013221A (es) | 2019-06-24 |
| ZA201807509B (en) | 2022-04-28 |
| US20190134017A1 (en) | 2019-05-09 |
| EP3448851B8 (en) | 2022-04-27 |
| AU2017258781A1 (en) | 2018-11-22 |
| MX382630B (es) | 2025-03-13 |
| ES2912921T3 (es) | 2022-05-30 |
| RU2018138054A3 (https=) | 2020-07-15 |
| KR20190003608A (ko) | 2019-01-09 |
| CN109476635B (zh) | 2021-07-13 |
| WO2017190086A1 (en) | 2017-11-02 |
| AU2017258781B2 (en) | 2021-09-02 |
| CA3022395C (en) | 2024-11-05 |
| KR102498741B1 (ko) | 2023-02-10 |
| EP3448851B1 (en) | 2022-03-23 |
| US20230119547A1 (en) | 2023-04-20 |
| JP6931695B2 (ja) | 2021-09-08 |
| JP2019515956A (ja) | 2019-06-13 |
| AU2017258781C1 (en) | 2022-03-03 |
| US11497738B2 (en) | 2022-11-15 |
| NZ747987A (en) | 2025-05-30 |
| RU2018138054A (ru) | 2020-05-29 |
| CA3022395A1 (en) | 2017-11-02 |
| EP3448851A1 (en) | 2019-03-06 |
| CN109476635A (zh) | 2019-03-15 |
| IL262708A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE060711T2 (hu) | Makrociklusos vegyületek betegségek kezelésére | |
| IL262708B (en) | Di-substituted pyrazole compounds for the treatment of diseases | |
| IL253062A0 (en) | Pyrazine compounds for the treatment of infectious diseases | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| IL264143B (en) | Processes for preparing olaparib | |
| LT3416631T (lt) | Terapiniai agentai, skirti neurodegeneracinių ligų gydymui | |
| HUE059694T2 (hu) | Készítmény rák kezelésére | |
| PL3169328T3 (pl) | Pochodne chinoliny do leczenia chorób zapalnych | |
| EP3445750A4 (en) | THERAPEUTIC COMPOUNDS | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| HUE051296T2 (hu) | Benzoxazinon-származékok bõrbetegségek kezelésére | |
| IL268693B (en) | Compounds for the treatment of glycogen storage disorders | |
| HUE053443T2 (hu) | Heteroaril vegyületek szembetegségek kezelésére | |
| HUE060517T2 (hu) | Immunhiányos betegség kezelésére szolgáló eljárások | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| IL259297A (en) | Heterocyclic compounds for the treatment of disease | |
| PL3463328T3 (pl) | Seladelpar do leczenia pierwotnego zapalenia dróg żółciowych | |
| PL3458067T3 (pl) | Leczenie chorób neurologicznych | |
| KR20180084983A (ko) | 암의 치료를 위한 피리미도-피리미다지논의 용도 |